• LAST PRICE
    0.5410
  • TODAY'S CHANGE (%)
    Trending Up0.0184 (3.5209%)
  • Bid / Lots
    0.5394/ 5
  • Ask / Lots
    0.5448/ 11
  • Open / Previous Close
    0.5300 / 0.5226
  • Day Range
    Low 0.5250
    High 0.5480
  • 52 Week Range
    Low 0.3630
    High 5.8299
  • Volume
    368,816
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 0.5226
TimeVolumeELEV
09:32 ET210750.5329
09:35 ET171050.5299
09:37 ET60650.532
09:42 ET10000.5348
09:46 ET28910.5333
09:48 ET1000.5333
09:50 ET1000.5336
09:53 ET59290.5363
09:55 ET6000.5336
09:57 ET1000.5363
10:00 ET1000.5336
10:06 ET45970.544999
10:08 ET1000.545
10:11 ET20000.54469
10:13 ET10330.543221
10:15 ET2000.548
10:18 ET3200.548
10:20 ET4170.546
10:24 ET58900.5444
10:26 ET1000.5411
10:27 ET1000.5444
10:29 ET6500.5413
10:33 ET4990.5412
10:36 ET7000.5412
10:42 ET11000.5476
10:44 ET2000.5408
10:47 ET5660.5442
10:49 ET1000.5444
10:51 ET117270.5444
10:54 ET61060.54
11:02 ET24090.5399
11:03 ET1440.535301
11:07 ET1000.5358
11:12 ET2000.53755
11:14 ET210120.5429
11:16 ET1000.5428
11:18 ET60000.5359
11:21 ET1000.5428
11:27 ET4440.5411
11:30 ET1000.5411
11:32 ET271330.5414
11:34 ET10830.5411
11:36 ET6570.5405
11:39 ET2710.5379
11:45 ET1000.5425
11:48 ET499840.5425
11:50 ET18160.543
11:52 ET2000.543
11:54 ET3840.5449
12:06 ET13770.5448
12:12 ET2310.54155
12:15 ET1000.5437
12:19 ET13000.5437
12:26 ET2000.5384
12:35 ET33000.5436
12:37 ET2000.5397
12:42 ET50000.5417
12:44 ET3000.5402
12:48 ET4000.5402
12:50 ET2000.5417
12:55 ET1000.5437
01:00 ET10000.5437
01:02 ET17490.5436
01:04 ET154550.5436
01:06 ET1000.543
01:08 ET109000.5405
01:09 ET95760.5429
01:11 ET17540.5404
01:13 ET12000.5397
01:27 ET1000.5383
01:33 ET1000.5397
01:36 ET2000.5423
01:42 ET6950.5398
01:44 ET1000.5423
01:45 ET2800.5398
01:47 ET6000.5429
01:56 ET34000.5404
01:58 ET8990.5405
02:00 ET13180.5404
02:02 ET5480.5404
02:03 ET1000.5448
02:05 ET4000.5406
02:07 ET7980.5406
02:09 ET5000.5413
02:12 ET8000.5405
02:14 ET3880.5403
02:16 ET1000.5403
02:25 ET2000.5448
02:27 ET54000.5448
02:30 ET8000.5417
02:32 ET77620.545
02:36 ET3970.5389
02:38 ET6000.539
02:39 ET6000.5367
02:41 ET4000.5365
02:43 ET9790.538
02:45 ET6620.5353
02:48 ET75070.5355
02:50 ET13000.5384
02:52 ET3990.5355
02:54 ET3000.5355
02:56 ET17470.5354
02:57 ET4240.5353
02:59 ET2000.535
03:01 ET54000.5381
03:03 ET8500.5381
03:06 ET3000.5351
03:08 ET6910.5366
03:10 ET6000.5352
03:12 ET37590.536549
03:15 ET53270.5363
03:17 ET3000.538
03:19 ET6000.536
03:21 ET3000.536
03:24 ET2000.5382
03:26 ET3990.5381
03:28 ET5000.5376
03:30 ET38000.5397
03:32 ET8880.5372
03:33 ET116270.5374
03:35 ET18980.5378
03:37 ET13940.5373
03:39 ET62310.5368
03:42 ET4000.5362
03:44 ET9320.5369
03:46 ET6000.5389
03:48 ET23120.541
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesELEV
Elevation Oncology Inc
30.9M
-0.6x
---
United StatesOCEA
Ocean Biomedical Inc
31.2M
-0.3x
---
United StatesIBO
Impact Biomedical Inc
31.3M
-7.1x
---
United StatesLIANY
LianBio
31.3M
-0.4x
---
United StatesACXP
Acurx Pharmaceuticals Inc
30.1M
-1.6x
---
United StatesITRM
Iterum Therapeutics PLC
30.0M
-0.6x
---
As of 2024-11-05

Company Information

Elevation Oncology, Inc. is an oncology company. The Company is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021 is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1 (IgG1) mAb that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. EO-3021 is designed to bind to Claudin 18.2 on the cell surface and is internalized, upon which the linker is cleaved in the lysosome to release the MMAE payload, a potent anti-mitotic agent. Its second program is an ADC designed to target HER3, which is overexpressed across solid tumors.

Contact Information

Headquarters
101 Federal Street, Suite 1900BOSTON, MA, United States 02110
Phone
716-371-1125
Fax
302-697-4597

Executives

Chairman of the Board
Steven Elms
President, Chief Executive Officer, Director
Joseph Ferra
Chief Financial Officer
Tammy Furlong
Chief Scientific Officer
David Dornan
Chief Medical Officer
Valerie Jansen

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$30.9M
Revenue (TTM)
$0.00
Shares Outstanding
59.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.26
EPS
$-0.84
Book Value
$1.29
P/E Ratio
-0.6x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.